Japan does not mandate mock audits or self-inspections before official drug quality audits. However, pharmaceutical companies often conduct them voluntarily to ensure compliance with Good Manufacturing Practices (GMP) and to identify potential issues. These proactive measures help companies prepare for official audits by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).
